Oman Medical Journal (Jul 2023)

Development and Validation of R-hf Risk Score in Acute Heart Failure Patients in the Middle East

  • Rajesh Rajan,
  • Mohammed Al Jarallah,
  • Ibrahim Al-Zakwani,
  • Raja Dashti,
  • Kadhim Sulaiman,
  • Prashanth Panduranga,
  • Peter A Brady,
  • Zhanna Kobalava

DOI
https://doi.org/10.5001/omj.2023.89
Journal volume & issue
Vol. 38, no. 4
pp. e529 – e529

Abstract

Read online

Objectives: The Rajan’s heart failure (R-hf) score was proposed to aid risk stratification in heart failure patients. The aim of this study was to validate R-hf risk score in patients with acute decompensated heart failure. Methods: R-hf risk score is derived from the product estimated glomerular filtration rate (mL/min), left ventricular ejection fraction (%), and hemoglobin levels (g/dL) divided by N-terminal pro-brain natriuretic peptide (pg/mL). This was a multinational, multicenter, prospective registry of heart failure from seven countries in the Middle East. Univariable and multivariable logistic regression was applied. Results: A total of 776 patients (mean age = 62.0±14.0 years, 62.4% males; mean left ventricular ejection fraction = 33.0±14.0%) were included. Of these, 459 (59.1%) presented with acute decompensated chronic heart failure. The R-hf risk score group (≤ 5) was marginally associated with a higher risk of all-cause cumulative mortality at three months (adjusted odds ratio (aOR) = 4.28; 95% CI: 0.90–20.30; p =0.067) and significantly at 12 months (aOR = 3.84; 95% CI: 1.23–12.00; p =0.021) when compared to those with the highest R score group (≥ 50). Conclusions: Lower R-hf risk scores are associated with increased risk of all-cause cumulative mortality at three and 12 months.

Keywords